2025 · 2nd Quarter (Apr 1 - June 30)

EISAI, INC.

Filed by CROSSROADS STRATEGIES, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 19, 2025
Income: $50,000.00
Expenses: Not reported
Registrant: CROSSROADS STRATEGIES, LLC
Client: EISAI, INC.
Filing UUID: 97dea785-a766-4881-a7f7-1e28e471be86
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

Literal federal measure citations: H.R.1

TRD · Trade (domestic/foreign)

Issues related to supply chain and tariffs.

HCR · Health Issues

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Literal federal measure citations: S.891

MMM · Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

TAX · Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.

Literal federal measure citations: H.R.1

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.